SGMIB-ZT-199

SGMIB-ZT-199 is a radiopharmaceutical tracer designed to target the Human Epidermal Growth Factor Receptor 2 (HER2) for the diagnosis and molecular imaging of metastatic breast cancer. It consists of the ZT-199 nanobody—a camelid-derived single-domain antibody fragment (sdAb) with high affinity for HER2—labeled with radioisotopes such as Gallium-68 (68Ga) for PET imaging or Iodine-131 (131I) for SPECT imaging or potential therapy. The tracer utilizes the N-succinimidyl 4-guanidinomethyl-3-iodobenzoate (SGMIB) prosthetic group, which acts as a residualizing linker. This specific chemical modification is intended to enhance the intracellular retention of radioactivity following the internalization of the HER2-bound complex, thereby improving the sensitivity of tumor detection and providing clearer imaging contrast in metastatic lesions. The drug is currently being evaluated to provide a non-invasive assessment of HER2 status across various tumor sites in patients with breast cancer.

Other names

[131I]SGMIB-ZT-199[68Ga]SGMIB-ZT-19968Ga-SGMIB-ZT-199131I-SGMIB-ZT-199Ga-68 SGMIB-ZT-199Ga68 SGMIB-ZT-199Ga 68 SGMIB-ZT-199I-131 SGMIB-ZT-199I131 SGMIB-ZT-199I 131 SGMIB-ZT-199